248
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Use of the self-controlled case series method in drug safety assessment

, , , , &
Pages 337-340 | Published online: 15 Mar 2011

Bibliography

  • Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009;32(1):19-31
  • Farrington P, Pugh S, Colville A, A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345(8949):567-9
  • Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009;18(1):7-26
  • Grosso A, Douglas I, Hingorani AD, Inhaled tiotropium bromide and risk of stroke. Br J Clin Pharmacol 2009;68(5):731-6
  • Grosso A, Douglas I, Hingorani A, Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009;4(3):e4720
  • Grosso A, Douglas I, Hingorani A, Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008;66(5):689-94
  • Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143(11):1165-73
  • Whitaker H, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25(10):1768-97
  • Henriksson M, Palmer S, Chen R, Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. BMJ 2010;340:b5606
  • Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. N Engl J Med 2007;357(22):2219-21
  • Kazi D. Rosiglitazone and implications for pharmacovigilance. BMJ 2007;334(7606):1233-4
  • Almenoff JS, Pattishall EN, Gibbs TG, Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82(2):157-66
  • Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006;29(2):175-81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.